Campath-1H: Clinical Trials

66 trials of Campath-1H, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed, 18 terminated, 5 active not recruiting, 5 recruiting. 50 Phase 2, 20 Phase 1, 5 Not applicable, 3 Phase 4, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 250Completed 29, Terminated 12, Recruiting 5, Active not recruiting 3, Withdrawn 1
Phase 120Terminated 8, Completed 7, Recruiting 3, Active not recruiting 2
Not applicable5Completed 2, Terminated 2, Active not recruiting 1
Phase 43Completed 2, Terminated 1
Phase 32Completed 2

Follow Campath-1H: new trials by email Literature Review of Campath-1H trials Research Report on Campath-1H

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
Daratumumab, Alemtuzumab, Sirolimus - Sickle Cell Disease
Phase 2RecruitingChildren's National Research Institute122024-04-032025-09-26
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy - Sickle Cell Disease
Phase 1Active not recruitingCity of Hope Medical Center202022-07-132026-07-30
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
Phase 1CompletedM.D. Anderson Cancer Center152020-01-152024-10-10
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea - Sickle Cell Anemia, Beta-thalassemia Major
Phase 1 / Phase 2RecruitingPaul Szabolcs52018-08-022026-08-13
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Cyclophosphamide, Mesna, Rituximab - Systemic Sclerosis, Diffuse Sclerosis Systemic
Phase 2RecruitingPaul Szabolcs82018-07-312026-08-14
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab - Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Phase 1 / Phase 2RecruitingPaul Szabolcs82018-04-192026-01-13
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
Alemtuzumab, Etoposide, Dexamethasone - Leukemia
Phase 2CompletedM.D. Anderson Cancer Center182015-09-232024-01-17
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center32013-12-272019-07-16
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan - SCID, Omenn's Syndrome
Not applicableActive not recruitingMasonic Cancer Center, University of Minnesota572012-09-042026-06-17
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
alemtuzumab, fludarabine, sirolimus - Ewing Sarcoma, Gastrointestinal Tumor
Phase 1CompletedSt. Jude Children's Research Hospital232012-08-202026-02-06
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
Campath-1H, Clofarabine, Melphalan - Lysosomal Storage Disease, Peroxisomal Disorder
Not applicableCompletedMasonic Cancer Center, University of Minnesota32012-07-112017-12-05
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
alemtuzumab, Fludarabine, Cyclosporins - Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome
Phase 2Active not recruitingBoston Children's Hospital402012-07-012026-03-27
Autologous Stem Cell Transplantation for Crohn's Disease
autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG - Crohn's Disease
Phase 1 / Phase 2RecruitingPaul Szabolcs202012-06-262025-12-15
Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
Palifermin, Alemtuzumab - Multiple Sclerosis
Phase 1 / Phase 2TerminatedCambridge University Hospitals NHS Foundation Trust402012-06-012019-04-30
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Fludarabine, Melphalan, Alemtuzumab - Leukemia, Lymphoma
Phase 2TerminatedM.D. Anderson Cancer Center162012-02-012016-03-17
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab - CLL, SLL
Phase 2TerminatedDana-Farber Cancer Institute302011-12-012023-08-29
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus - Sickle Cell Disease
Phase 1 / Phase 2Active not recruitingUniversity of Illinois at Chicago452011-11-112026-07-08
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
alemtuzumab, ofatumumab, biopsy - Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Phase 2Active not recruitingNorthwestern University532011-06-012025-05-23
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Phase 1 / Phase 2CompletedMayo Clinic222011-01-012020-06-23
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Phase 2CompletedNational Cancer Institute (NCI)662010-12-142023-04-04

Showing 20 of 66. Sign in to see all of them.

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (17)  ·  Leukemia (14)  ·  Lymphoma (9)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (9)  ·  Hodgkin Disease (8)  ·  Lymphoma, Non-Hodgkin (7)  ·  Leukemia, Myeloid, Acute (6)  ·  Myelodysplastic Syndromes (6)  ·  Anemia, Aplastic (5)  ·  Multiple Myeloma (5)  ·  Recurrence (5)  ·  Anemia, Sickle Cell (4)  ·  Lymphoma, B-Cell, Marginal Zone (4)  ·  Lymphoma, Mantle-Cell (4)  ·  Myeloproliferative Disorders (4)

Sponsors

M.D. Anderson Cancer Center (15)  ·  Baylor College of Medicine (6)  ·  Masonic Cancer Center, University of Minnesota (5)  ·  Northwestern University (5)  ·  National Cancer Institute (NCI) (4)  ·  Paul Szabolcs (4)  ·  Fred Hutchinson Cancer Center (3)  ·  Dana-Farber Cancer Institute (2)  ·  Mayo Clinic (2)  ·  St. Jude Children's Research Hospital (2)  ·  University of Miami (2)  ·  University of Wisconsin, Madison (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Boston Children's Hospital (1)  ·  Cambridge University Hospitals NHS Foundation Trust (1)

Countries

United States (61)  ·  Italy (3)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Iran (1)  ·  Norway (1)

Top investigators

Malcolm K Brenner, MD (3)  ·  Paul Orchard, MD (3)  ·  Paul Szabolcs, MD (3)  ·  Brenda Sandmaier (2)  ·  Issa F. Khouri, MD (2)  ·  Issa F. Khouri, MD, BS (2)  ·  Alasdair Coles, Phd FRCP (1)  ·  Alessandra Ferrajoli, M.D. (1)  ·  Alessandra Ferrajoli, MD (1)  ·  Anas Younes, M.D. (1)  ·  Anna Pawlowska (1)  ·  Anne Angiolillo (1)  ·  Ardeshir Ghavamzadeh, MD (1)  ·  Brando Triplett, MD (1)  ·  Brandon Triplett, MD (1)

Results publications

PMID 23547837, PMID 24477186, PMID 16123718, PMID 17018123, PMID 18339140, PMID 19863336, PMID 19900571, PMID 21454450, PMID 21566092, PMID 21586746, PMID 21981661, PMID 22067384, PMID 23641902, PMID 25078310, PMID 29226570, PMID 30322319, PMID 31063156, PMID 34086408, PMID 34492682, PMID 35173720, PMID 41536780, PMID 42309868

NIH funding

P30CA015704 (3), U10CA031946 (3), P01CA018029 (2), 2008 (1), P30CA014236 (1), P30CA033572 (1), U01CA097452 (1), U10CA021115 (1), U10CA180821 (1)